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Adverse sensory changes prevent the addition of highly bioavailable ferrous sulfate (FeSO4) to most wheat flours. Poorly absorbable reduced Fe
powders are commonly used. Encapsulation of FeSO4 can overcome these sensory changes, but the particle size of commercial compounds is too
large to be used by flour mills. The first objective of the study was to measure the efficacy in wheat flour of two newly developed Fe compounds, an
H-reduced Fe powder (NutraFinee RS; North America Ho¨gana¨s High Alloys LLC, Johnstown, PA, USA) and small particle-sized (40mm) encap-
sulated FeSO4. As a second objective, the microcapsules were evaluated as a vehicle for iodine fortification. A randomised, double-blind controlled
intervention trial was conducted in Kuwaiti women (n 279; aged 18–35 years) with low body Fe stores (serum ferritin (SF) ,25mg/l) randomly
assigned to one of three groups (20 mg Fe as NutraFinee RS, 10 mg Fe as encapsulated FeSO4 and 150mg iodine, or no fortification Fe) who
consumed wheat-based biscuits 5 d per week. At baseline and 22 weeks, Hb, SF, transferrin receptor, urinary iodine and body Fe stores were
measured. Relative to control, mean SF in the encapsulated FeSO4 group increased by 88 % (P,0·001) and body Fe stores increased from
20·96 to 2·24 mg/kg body weight (P,0·001), while NutraFinee RS did not significantly increase SF or body Fe stores. The median urinary
iodine concentration increased from 140 to 213mg/l (P,0·01). NutraFinee RS added at double the amount of Fe as FeSO4 was not efficacious
in improving Fe status. The newly developed microcapsules were highly efficacious in improving both Fe stores and iodine status.
Iron fortification: Iron-deficiency anaemia: Iodine fortification: Intervention trials: Women
Fe-deficiency anaemia and iodine-deficiency disorders are
common in children and women of childbearing age in both
developing and industrialised countries(1,2). Food fortification
is considered to be the most cost-effective, long-term,
population-based strategy to combat micronutrient malnu-
trition(1,3,4). Worldwide, cereals are the foods most often
fortified with Fe and other micronutrients, although iodine
has been traditionally added to salt. The USA, Canada, the
UK, and several Latin American, African, Middle East and
Central Asia countries require Fe to be added to low-extrac-
tion wheat flour(5,6). Many countries also have mandatory
iodine fortification of salt(7,8).
Unfortunately, the well-absorbed, water-soluble Fe
compounds, such as ferrous sulfate (FeSO4), may cause
sensory changes in stored wheat flours(4,9), and therefore the
less soluble Fe compounds, such as elemental Fe powders,
have been commonly used for cereal fortification. They are
relatively inexpensive and cause fewer organoleptic problems
compared with ferrous sulfate or other soluble Fe com-
pounds(4,5). However, most elemental Fe powders are poorly
absorbed. Electrolytic Fe and reduced Fe are the elemental
Fe powders most commonly added to wheat flour. WHO
guidelines(1) recommend electrolytic Fe as the only elemental
Fe powder to be used in food fortification and recommend that
it should be added to wheat flour at twice the level of ferrous
sulfate so as to compensate for its lower bioavailability. The
WHO guidelines further consider that Fe absorption from
H-reduced Fe powders is too low for it to be recommended
for wheat flour fortification but they recommend that
H-reduced Fe could be reconsidered as a fortificant after
further studies.
Encapsulation of ferrous sulfate can reduce Fe-mediated
sensory changes in foods(10) and is recommended by WHO
for fortification of wheat flour(1). However, commercially
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available products are too large to be used by most flour mills,
because they will not pass the small sieve diameters used in
the final stages of processing. The fat-based capsule used to
enrobe the Fe is a useful carrier of other micronutrients and
offers some protection against storage and processing losses.
We have previously shown that fat-based microcapsules
containing Fe and iodine improve Fe and iodine status
when used to fortify salt. Double fortification of foods with
Fe and iodine may be particularly beneficial because
Fe-deficiency anaemia reduces the efficacy of iodine prophy-
laxis(10 – 12).
Although salt iodisation is the preferred strategy for iodine
prophylaxis(1), it is ineffective where salt is not the major
condiment (for example, in Southeast Asia, where it is
replaced by soya and fish sauce) or where the presence of
multiple small salt producers makes installation of fortification
infrastructure difficult. In these situations, alternate vehicles
for iodine should be explored(13). Wheat flour could be a
valuable alternative vehicle for iodine fortification and
encapsulation could help ensure iodine stability.
An efficacy study in Thailand(14) with Fe-fortified wheat
flour snacks fed to women for 6 d per week over 35 weeks
reported that electrolytic Fe (A-131; North America Ho¨gana¨s
High Alloys LLC, Johnstown, PA, USA) and H-reduced
Fe (AC-325; North America Ho¨gana¨s High Alloys LLC)
had efficacies of 77 and 49 %, respectively, relative to ferrous
sulfate. Encouraged by the relatively high efficacy of the
commercial H-reduced Fe AC-325, the manufacturer Ho¨gana¨s
attempted to further improve the bioavailability of their
H-reduced Fe powder by modifying the manufacturing process
so as to increase the porosity of the Fe powder and its
solubility in dilute acid(15). The newly developed H-reduced
Fe powder has been commercialised under the name
NutraFinee RS.
The present efficacy study was thus designed to evaluate
two newly developed Fe compounds for wheat flour fortifica-
tion: an H-reduced Fe powder (NutraFinee RS) and small
particle-sized encapsulated ferrous sulfate. By incorporating
potassium iodate into the lipid shell of the microcapsules,
their potential for iodine fortification was also investigated.
The capsules had a mean particle size of approximately
40mm and should not be retained by the sieves in the flour
mill. The study was carried out in young women in Kuwait
over a 22-week period during which they regularly consumed
Fe- and Fe/iodine-fortified wheat flour biscuits and their Fe
and iodine status was monitored.
Materials and methods
Hydrogen-reduced iron powder
H-reduced Fe (NutraFinee RS, mean particle size (d50)
approximately equal to 30mm) was manufactured by
North America Ho¨gana¨s High Alloys LLC. The manufacturer
modified the traditional manufacturing process to produce an
Fe powder of greater porosity and a 20 % greater solubility
in dilute acid as compared with the previously marketed
H-reduced Fe powder (AC-325). It was assumed that a greater
solubility rate in dilute acid would improve Fe absorption in
human subjects(15). It should be noted that the vast majority
of Fe powders are manufactured to meet the needs of the
automobile industry and that only a small surplus of these
powders is used for food fortification. NutraFinee RS is the
first Fe powder developed exclusively for food fortification.
Microcapsules containing iron and iodine
A single-step, spray-cooling technique previously described for
salt fortification was modified and optimised to build microcap-
sules containing Fe and iodine for wheat flour fortification(16).
The components for the capsule were micronised FeSO4
monohydrate with a mean particle size (d50) of , 5mm
(Dr Paul Lohmann GmbH KG, Emmerthal, Germany) and
potassium iodate (Riedel-de Haen, Hannover, Germany).
The Fe and iodine were coated with hydrogenated palm oil
(Rau Fette, Neuss, Germany) with a melting point of 658C.
For the capsules to be suitable for wheat flour fortification, a
d90 , 150mm is required in order to pass through the sieves
(150mm) commonly used by the milling industry. Also, the
Fe compound:capsule ratio should be $ 50:50 to ensure Fe
bioavailability(10). To meet this requirement, several changes
were made in our previously published spray-cooling pro-
cess(16). The highly viscous suspension of fat, ferrous sulfate,
potassium iodate and emulsifiers was heated to 85 ^ 58C and
then passed via a piston pump (Rotary piston pump; CATAG
AG, Basel, Switzerland) into a stainless-steel, cold-spraying
tower (Schidlin AG, Zurich, Switzerland), atomised with a
two-fluid nozzle (SSCO-Spraying Systems AG, Pfa¨ffikon
SZ, Switzerland) using air as the second medium, and then
cooled with the use of partially evaporated liquid N2.
The final spraying parameters used were: pump water tem-
perature, 82·58C; tower water temperature, 90·58C; air
temperature, 908C; pump pressure, 2·0 bars; tower cooling
temperature, 2 40 ^ 58C.
Production of fortified wheat flour-based biscuits
Wheat flour biscuits (‘Petite Beurre’) were manufactured in
200 kg batches from a slightly modified standard commercial
recipe at the Kuwaiti Flour Mills and Bakeries Company
using unfortified low-extraction flour. The recipe per kg
flour was as follows: sugar, 275 g; ghee, 125 g; dextrose,
25 g; flavours, 15 g; baking agents, 14·3 g; egg yolk, 10 g;
salt, 7·5 g; malt, 4 g; water, 200 g. To ensure a homogeneous
mixture of microcapsules and wheat flour, 10 kg wheat flour
was premixed with the appropriate amount of microcapsules
or H-reduced Fe before adding the remaining ingredients.
One package of four biscuits (each biscuit weighing 6·25 g)
was designed to provide 10 mg added Fe as encapsulated
FeSO4 and 150mg iodine or 20 mg NutraFinee RS. Due to
the high Fe dose in the fortified biscuits used for the interven-
tion study, sodium citrate was added at a 5:1 molar ratio to
reduce the metallic flavour and maintain the shelf life; this
amount of citrate was also added to identical non-fortified
biscuits. During the feeding trial, the biscuits were produced
at 0, 8 and 16 weeks in colour- and letter-coded batches
under close supervision. They were stored under controlled
conditions following the quality standards for temperature
and humidity at the Kuwaiti Flour Mills and Bakeries
Company and transported on demand to the study sites.
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Sensory testing
Wheat flour fortified with the test compounds was stored for
3 months at 50 and 75 % relative humidity and 25 and 378C
and Fe-mediated colour changes were investigated in the
flour. Potential sensory changes in the biscuits were evaluated
using triangle tests performed in Kuwaiti and Swiss adults
(twenty-four subjects at each site). During the triangle test,
three coded samples (two control unfortified samples plus
one test Fe-fortified sample) of the biscuits were given in a
random order in a private setting. The panellists were asked
to indicate which sample differed in colour, flavour or texture
from the other two samples.
Solubility and X-ray diffraction studies
H-reduced Fe (AC-325; North America Ho¨gana¨s High Alloys
LLC), electrolytic Fe (A-131; North America Ho¨gana¨s High
Alloys LLC) and FeSO4 monohydrate (Crown Technology,
Indianapolis, IN, USA) were obtained from the SUSTAIN
Fe pool, which was used for a recent comparison of different
elemental Fe powders(15). These compounds were compared
with NutraFinee RS in a series of in vitro solubility tests.
The solubility of elemental Fe powders in dilute acid was
tested as described previously(15). A total of 20 mg Fe was
added to 250 ml aqueous solution of 0·1 M-HCl corresponding
to pH 1 and mixed in an orbital shaker at 150 rpm and 378C
(Aqua shaker; Adolf Ku¨hner, Basel, Switzerland). The percen-
tage of dissolved Fe was measured in a 1·5 ml sample after 15,
30 and 60 min.
After centrifugation for 4 min at 11 600 g, the Fe content of
the supernatant fraction solution was measured by atomic
absorption spectroscopy. The elemental Fe powder X-ray dif-
fraction patterns were recorded with a Bruker D8 Advance
(40 kV; 40 mA; l ¼ 1·54 nm) at a scan speed of 0·58/min
and 108 , 2q , 708.
Efficacy study
The feeding study was carried out in Kuwait City, the capital
of the State of Kuwait.
Subjects and study design
Women aged 18–35 years were recruited from two colleges in
Kuwait – College for Women, Kuwait University (CfW) and
the Nursing College, Public Authority for Applied Education
& Training (NC). The present study was conducted according
to the guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved by the
ethical committees of the Swiss Federal Institute of Technol-
ogy in Zurich and the Ministry of Health in Kuwait. Written
informed consent was obtained from all subjects; if subjects
were aged less than 21 years, consent was obtained from
their parents.
Blood was drawn from the volunteers and serum ferritin (SF)
measured. Subjects were invited to join the intervention trial if:
(1) they had low Fe stores, defined as a SF concentration , 25
mg/l; (2) were not pregnant or planning pregnancy; (3) had no
chronic medical illnesses; (4) did not use vitamin and mineral
supplements. Subjects meeting the inclusion criteria were
randomly assigned to three groups receiving biscuits fortified
with either H-reduced Fe (NutraFinee RS) or encapsulated
FeSO4 and potassium iodate or the non-fortified biscuits. The
biscuits were consumed 5 d per week in the morning pause
between lectures at the colleges. If a subject was absent from
college, the missed pack of biscuits was compensated by
provision of two packs of biscuits the following day. Subjects
were instructed to consume the biscuits at least 1 h away from
meals and without coffee and tea; only water was provided
with the biscuits. On scheduled holidays, the subjects were
provided with a sufficient amount of biscuits, packaged into
individual daily portions, and instructed to consume a pack of
biscuits each day away from meals and to report if they were
not consumed.
At baseline and endpoint, weight and height were measured,
and a spot urine sample was collected for measurement of
urinary iodine concentration of those subjects who accepted
to be part of the iodine pilot study. Whole blood was collected
by venepuncture for measurement of Hb, SF, serum transferrin
receptor and C-reactive protein. The study design was
randomised double blind and the intervention period was
from December 2006 to May 2007.
Laboratory analysis
Blood samples were transported on ice to Al-Sabah Hospital in
Kuwait City. Hb was measured in whole blood (refrigerated and
measured on the same day of collection) with the use of a haema-
tology analyser (Cell-Dyn 4000; Abbott Diagnostics, Abbott
Park, IL, USA) with three-level control material provided by
the manufacturer. Blood was centrifuged on the day of collec-
tion, and the serum was divided into samples and frozen at
2608C. SF was measured using RIA (Ramco, Houston, TX,
USA), and transferrin receptor concentrations were measured
using ELISA-immunoassays (Ramco). High-sensitivity C-reac-
tive protein was measured with a BN Pro Spec analyser (Dade
Behring, Newark, DE, USA). Urinary iodine samples were
sampled and frozen at 2208C and were measured using the
Sandell–Kolthoff reaction as modified by Pino et al. (17,18).
The phytic acid content of the baked snacks was measured by
the modified Makower method(19). Anaemia was defined as
Hb , 120 g/l. Fe deficiency was defined as SF , 15mg/l. The
cut-off for serum transferrin receptor was set at .8·5 ng/ml.
Fe-deficiency anaemia was defined as anaemia and Fe deficiency
by the above-mentioned criteria(1). Body Fe was estimated from
the transferrin receptor:SF ratio(20). SF measurements from sub-
jects with elevated C-reactive protein (.10 mg/l) were excluded
from the statistical analysis. The iodine content of the snacks and
the microcapsules was measured by inductively coupled
plasma MS (Thermo Finnigan, San Jose, CA, USA)(21) or
X-ray fluorescence (PANalytical, Almelo, The Netherlands;
http://www.paralytical.com/index.cfm?pid=283), respectively.
The Fe content of the baked snacks and the microcapsules was
measured by atomic absorption spectroscopy (Spectra AA-50;
Varian, Palo Alto, CA, USA). The particle size of the Fe
compounds was measured using laser diffraction spectrometry
(Malvern Mastersizer X; Rennes, Lausanne, Switzerland),
and microcapsule morphology determined by scanning
electron microscopy (S 900; Hitachi, Tokyo, Japan). To measure
colour changes, 10 g fortified flour was transferred into a
glass container; colour determination on the Hunter scale was
R. Biebinger et al.1364
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established with the use of a Spectral Photometer (Chroma
Meter CR-310; Minolta, Osaka, Japan) by using an illuminant
D65 (average daylight, including UV spectra) setting and a 08
observer angle with a large reflectance spectrum as previously
described(16,22).
Statistical analyses
Data processing and analysis were performed using Microsoft
Excel 2002 (Redmond, WA, USA) and SPSS 13.0 (SPSS Inc.,
Chicago, IL, USA). Data which were not normally distributed
(SF) were log transformed. Solubility data were compared by
unpaired t tests. Two-way ANOVA (time £ treatment) were
used to compare groups with Bonferroni post hoc testing.
For binary variables (Fe deficiency prevalence), x2 tests
were used to compare groups. Significance was set at P,0·05.
Results
Solubility in dilute acid and X-ray diffraction of elemental
iron powders
The results of the solubility of the elemental Fe powders in
0·1 M-HCl are shown Table 1. Dried ferrous sulfate was
virtually 100 % soluble after 15 min. After 30 min, Nutra-
Finee RS was 33·6 % soluble compared with 26·9 % solubility
for AC-325 H-reduced Fe and 71·6 % solubility for electro-
lytic Fe. The newly developed NutraFinee RS thus showed
a 20 % better solubility than the previous commercial
H-reduced Fe (AC-325) but was still 40 % less soluble in
dilute acid than electrolytic Fe (A-131). The X-ray diffraction
patterns (data not shown) indicated that H-reduced Fe (Nutra-
Finee RS) and electrolytic Fe (A-131) contained less iron
oxide as impurities than H-reduced Fe (AC-325).
Microcapsule characteristics
The capsules had a mean particle size of approximately 40mm
and the microcapsule:substrate ratio was approximately 50:50.
The mean Fe content of the microcapsule was 15·7 (SD 0·4) %
and the iodine content was 0·45 (SD 0·02) %. During spraying,
mean iodine losses were about 25 %; wheat flour storage and
the baking process produced no measurable iodine losses.
Sensory evaluations
In the flour storage trial, no significant difference in colour
could be detected after 3 months at different temperatures
and humidity conditions (data not shown). In the triangle
testing in both Kuwait and Switzerland, the fortified biscuits
were indistinguishable from the non-fortified biscuits in
colour, taste and texture.
Composition of biscuits
The mean Fe content was 0·35 (SD 0·05) mg per snack of 25 g
for the control biscuits, 10·2 (SD 0·9) mg per snack of 25 g for
the encapsulated FeSO4 biscuits and 20·1 (SD 0·9) mg per
snack of 25 g for the H-reduced Fe (NutraFinee RS) biscuits.
The mean phytic acid content of the biscuits was 59 (SD 2) mg
per 100 g and mean iodine content was 130 (SD 9) mg per
snack of 25 g. Fe content was checked for each batch with
no significant difference between the batches. Weight control
of the biscuits was conducted during production, and packa-
ging was started only after reaching optimal production
conditions.
Human efficacy trial
Table 2 shows the baseline characteristics of the screened and
selected subjects; a total of 279 out of 383 subjects met the
inclusion criteria and were randomly assigned to three
groups of ninety-three (control: CfW group, n 53; NC
group, n 40; NutraFinee RS: CfW group, n 47; NC group,
n 46; microcapsules: CfW group, n 55; NC group, n 38).
There were no significant differences among the three
groups in baseline anthropometrics, mean Hb, SF or serum
transferrin receptor.
A total of 65 % of the screened subjects completed the Fe
fortification efficacy study (control, n 61 (CfW group, n 37;
NC group, n 24); NutraFinee RS, n 63 (CfW group, n 28;
NC, n 35); microcapsules, n 57 (CfW group, n 32; NC
group, n 25)). Drop-outs were due to: (1) time constraints
(72 %); (2) changing residence (14 %); (3) illness (8 %);
(4) pregnancy (6 %). There were no significant differences in
baseline anthropometrics, Hb or SF characteristics comparing
the students by group who completed the study with those who
dropped out (data not shown).
In Table 3, the changes in Hb, SF, serum transferrin recep-
tor and body Fe stores are presented. There was no significant
change in Hb or the prevalence of anaemia in any group
during the study. Mean SF significantly increased from 10·5
(SD 6·5) mg/l at baseline to 19·8 (SD 10·5) mg/l after
22 weeks (P,0·001) and body Fe stores from 20·96 to
2·24 mg/kg body weight (P,0·001) in the ferrous sulfate
microcapsule group, which was also significantly higher as
compared with the control group (P,0·05). In contrast, Nutra-
Finee RS did not significantly increase SF or body Fe stores
as compared with the control group.
A total of 46 % (n 129) of the subjects in the Fe fortification
efficacy study accepted to participate in the iodine fortification
efficacy pilot study. Inclusion of the potassium iodate in the
capsule (n 44) significantly increased the median urinary
iodine from a baseline concentration of 140 (range 10–681)
to 213 (range 22–881) mg/l after 22 weeks, while there was
Table 1. Relative solubility of different elemental iron compounds*
(Mean values and standard deviations for three independent replicates)
Solubility in dilute acid (%)
H-reduced
(AC-325)†
NutraFinee
RS†
Electrolytic
(A-131)†
Time (min) Mean SD Mean SD Mean SD
15 21·3a 2·9 23·7a 3·4 54·7b 7·3
30 26·9a 0·2 33·6b 1·8 71·6c 2·9
60 35·7a 0·8 50·8b 0·3 93·4c 0·6
a,b,c Mean values within a row with unlike superscript letters were significantly differ-
ent (P,0·05).
* Ferrous sulfate ¼ 100.
† North America Ho¨gana¨s High Alloys LLC (Johnstown, PA, USA).
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no significant change in the median urinary iodine concen-
tration in the control group (n 43) (138 (range 9–470) mg/l).
The urine of the subjects who consumed biscuits with
NutraFinee RS was not analysed (n 42).
Discussion
Despite a high standard of living, the prevalence of anaemia
(15 %) and Fe deficiency (50 %) was relatively high in
young female Kuwaiti students (Table 2). These prevalence
values are, however, lower than those previously reported.
Eid et al. reported 26 % anaemia in Kuwaiti girls aged 6–17
years(23), Al-Awadi et al. reported 23 % anaemia in Kuwaiti
females aged 14–45 years(24) and, most recently, Jackson &
Al-Mousa found 30 % anaemia and 68 % Fe deficiency (as
measured by erythrocyte protoporphyrin) in Kuwaiti girls
aged 14–23 years(25). These studies were all made before
the introduction of the flour fortification programme in
2001. Since that date, wheat flour in Kuwait has been fortified
with 60 parts per million of reduced Fe powder manufactured
by the atomisation process, providing on average an extra
12 mg Fe/person per d in an average flour consumption of
about 200 g/person per d. As there is only one flour mill in
Kuwait, all of the wheat flour is fortified. However, the
Table 2. Characteristics of screened (n 383) and selected (n 279) Kuwaiti college women at base-
line screening
(Mean values and standard deviations or percentage prevalences)
Screened Selected
Characteristics Mean SD Mean SD
Age (years) 20·6 3·1 20·1 3·2
Height (cm) 159·8 5·6 159·9 5·5
Weight (kg) 63·8 15·9 63·7 15·0
BMI (kg/m2) 24·9 5·6 24·8 5·4
Hb (g/l) 130·9 10·4 130·1 10·7
Serum ferritin (mg/l) 18·9 17·7 10·9 6·8
Transferrin receptor (mg/l) 6·9 2·7 7·3 2·8
Body Fe stores (mg Fe/kg body weight) 0·9 4·0 20·7 3·5
Anaemia prevalence (%) 15 15
Prevalence of low Fe status (serum ferritin , 25mg/l) (%) 77 100
Prevalence of Fe deficiency (serum ferritin , 15mg/l) (%) 50 70
Prevalence of serum transferrin receptor .8·5 mg/l (%) 14 24
Table 3. Hb, serum ferritin, serum transferrin receptor, body iron stores and prevalence
of iron deficiency at baseline and 22 weeks
(Mean values and standard deviations or percentage prevalences)
Control
Encapsulated
FeSO4 þ iodinek NutraFinee RSk
Mean SD Mean SD Mean SD
Hb (g/l)
Baseline 128 11 131 10 131 10
22 weeks 125 11 131 9 129 9
Serum ferritin (mg/l)**
Baseline 11·2 7·1 10·5 6·5 11·1 7·1
22 weeks 15·1a†† 7·1 19·8b††† 10·5 14·6a†† 10·6
Serum transferrin receptor (mg/l)**
Baseline 7·1 3·1 7·5 4·9 7·2 2·6
22 weeks 7·5a 4·9 6·0b†† 1·5 6·7a 2·1
Body Fe status (mg Fe/kg body weight)**
Baseline 20·48 3·4 20·96 3·4 20·60 3·7
22 weeks 0·35a 3·96 2·24b††† 1·49 0·49a 3·4
Prevalence of Fe deficiency (serum ferritin , 15mg/l) (%)
Baseline 70 72 70
22 weeks 57‡‡ 42‡‡§§ 58‡‡
a,b Mean values within a row with unlike superscript letters were significantly different (P,0·05; ANOVA).
** Significant treatment £ time interaction (P,0·01; ANOVA).
Mean value was significantly different from that at baseline: †† P,0·01, ††† P,0·001.
‡‡ Prevalence was significantly different from that at baseline (P,0·01; x2 test).
§§ Prevalence was significantly different from that of the control group (P,0·01; x2 test).
kNutraFinee RS was manufactured by North America Ho¨gana¨s High Alloys LLC (Johnstown,
PA, USA). For details of the FeSO4 þ iodine microcapsules, see the Microcapsules containing iron
and iodine section.
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atomised form of reduced Fe is poorly absorbed and is not
recommended by WHO(1). This may explain the continued
high prevalence of Fe deficiency in Kuwaiti women.
The development of H-reduced NutraFinee RS powder was
an attempt to provide a less expensive H-reduced Fe powder
with improved bioavailability and good efficacy. The
powder had improved solubility in dilute acid by 20 % relative
to the previous commercial H-reduced Fe powder (AC-325)
(Table 1), but was still only about half that of electrolytic
Fe (Table 1). A similar experimental Fe powder developed
by Ho¨gana¨s called ‘Hi-Sol’ was previously reported by
Lynch & Bothwell(15) to have an equivalent solubility in
dilute acid as electrolytic Fe. For commercial reasons Ho¨gana¨s
chose to commercialise NutraFinee RS and not ‘Hi-Sol’.
Nevertheless, as AC-325 added to wheat flour biscuits in
Thailand had been previously reported to have an efficacy
of 49 % relative to ferrous sulfate in young women(14), it was
still highly surprising that the newly developed NutraFinee
RS had no efficacy in the present study in Kuwait, even
when added at double the amount of Fe as ferrous sulfate.
In contrast, the small particle-sized encapsulated ferrous
sulfate was highly efficacious.
Over the 22-week feeding study, the increase in body Fe
stores with 10 mg Fe per d as encapsulated ferrous sulfate
was 3·2 mg/kg body weight, compared with 1·1 mg/kg body
weight for the women consuming 20 mg Fe as H-reduced Fe
and 0·8 mg/kg body weight for the control women consuming
biscuits with no added Fe. The small but significant increase in
body Fe in the control group was due to a small increase in SF
(Table 3). The students were aware of their poor Fe status and,
although instructed not to change their eating habits, it is
possible that they modified their diet. The total dose of Fe
delivered during the intervention was approximately equal to
1·1 g as FeSO4 or approximately equal to 2·2 g as Nutra-
Finee RS. When these amounts are corrected, by subtracting
the increase in body Fe stores in the control group, the
mean increase in total body Fe due to fortification was
2·4 mg/kg body weight in the women consuming the encapsu-
lated ferrous sulfate biscuits, and 0·26 mg/kg body weight for
NutraFinee RS. When the total increase in body Fe stores
(increase in body Fe stores (mg/kg) multiplied by mean
body weight) is divided by the total Fe consumed during the
study, an estimate can be made of Fe absorption. Using this
approach we obtained an Fe absorption of approximately
equal to 13·8 % from ferrous sulfate and approximately
equal to 0·7 % from H-reduced Fe over the 22-week trial.
This percentage Fe absorption from encapsulated ferrous
sulfate in the present study is somewhat higher than that
from the Thailand study(14) recalculated at 20 weeks
(11·3 %); however, in that study, Fe absorption from
H-reduced Fe (AC-325) at 20 weeks was found to be 5·6 %,
which is much higher than the 0·7 % found for NutraFinee
RS in Kuwait. In the present study, it would have been
useful to have a direct comparison between NutraFinee RS,
electrolytic Fe and A-325 reduced Fe; however, such a large
study was not possible with the infrastructure and financial
resources available.
Several factors might have contributed to the lack of impact
of H-reduced Fe (NutraFinee RS) on body Fe stores in the
present study compared with the relatively good efficacy
of H-reduced Fe (AC-325) reported in the Thai study.
These factors can be divided into general subject factors,
which include compliance, dietary habits and baseline Fe
status, and factors influencing the solubility of the Fe powders
in the gastric contents during digestion. Compliance was
assured in the Thai study by a study coordinator being present
during the feeding of the biscuits, whereas in the Kuwait study
consumption of the fortified biscuits was not controlled and
may have been less than expected; however, since the study
design was double-blind and there were no differences in sen-
sory qualities of the snacks, there is no reason to believe that
compliance differed between the test groups. Also, although
traditional diets are different in Kuwait and Thailand, this
should not have influenced Fe absorption as the fortified
biscuits were consumed without other foods or drinks.
One factor that may have influenced the results is the
different baseline Fe status of the subjects. The Kuwaiti
subjects had negative body Fe stores (21 mg Fe/kg body
weight) as compared with positive body Fe stores (þ1 mg
Fe/kg body weight) in the Thai subjects. Data from a recent
study suggest that absorption of poorly soluble Fe compounds
is less up-regulated by low Fe status than absorption of readily
soluble compounds such as ferrous sulfate(26).
Differences in Fe status of study subjects, however, do not
appear to be enough to explain the complete lack of efficacy
of NutraFinee RS, which seems most likely to be due to
poor dissolution of the Fe powder in the gastric contents.
Dissolution in the acidic gastric contents is thought to be the
main factor governing the relative bioavailability of different
elemental Fe powders(15).
Factors that might influence gastric acid dissolution include
biscuit composition, the purity and microstructure of the Fe
powder, and impaired gastric acid secretion in the subjects.
There were, however, no major differences in the biscuit
recipes used in the Kuwaiti and Thai studies, although the
recipes varied slightly in fat and sugar content. The biscuits
in both studies were made from low-extraction wheat flour
that provided only modest amounts of phytic acid (,0·1 g/
100 g). It also seems unlikely that there were differences
in gastric acid secretion between the Kuwaiti and Thai
subjects. Helicobacter pylori infections can cause gastric
atrophy and greatly reduce gastric acid secretion(27).
However, such infections are more prevalent in populations
of low socio-economic status, which is not typical of young
Kuwaiti women.
Three further factors could explain the poor solubility of
NutraFinee RS in the gastric juice. These include an
improved purity relative to AC-325, a different polycrystalline
structure and insoluble oxides formed at the surface during the
biscuit baking procedure. The newly developed manufacturing
process for H-reduced Fe (NutraFinee RS) was modified to
increase powder porosity and decrease its impurities to a
level closer to electrolytic Fe. Data from the manufacturer
indicate that the amount of impurities was reduced from
0·47 % in AC-325 to 0·22 % for NutraFinee RS. This is
supported by data from the X-ray diffraction which show
that NutraFinee RS contains less iron oxide. While these
lower levels of impurities might have in some way decreased
the solubility of NutraFinee RS relative to A-325
H-reduced Fe, the similarly low levels of impurities in electro-
lytic Fe powder indicate that this is not the main factor
governing solubility.
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Little is known about the polycrystalline structure of Fe
powders produced by different manufacturing processes.
However, together with particle size and reactive surface
area, polycrystalline structure appears to be a major factor
governing Fe powder solubility in dilute acid. Electrolytic
Fe powders, irrespective of particle size, are more soluble
and have a different polycrystalline structure to reduced Fe
powders. Electrolytic Fe powders are produced by electrolysis
of Fe solutions whereas reduced Fe powders are manufactured
by heating Fe ores in kilns at high temperatures for many
days. It is possible that the new manufacturing process for
NutraFinee RS in some way changed the polycrystalline
structure of the powder so that it did not dissolve in the gastric
contents. A final explanation which needs to be checked is that
baking of the biscuits at 2008C may have caused insoluble
oxides to form on the surface of NutraFinee RS. These
oxides may have prevented the penetration of the gastric
acid and decreased solubility.
In contrast to the poor efficacy of NutraFinee RS, the small
particle-sized microcapsules of ferrous sulfate greatly
improved Fe status of the Kuwaiti students. Commercially
encapsulated ferrous sulfate has previously been reported to
be efficacious in salt(28). The novelty of the present study
was that the microcapsules were only 40mm in diameter
and, unlike the current larger particle-sized commercial
encapsulated sulfate, would not be retained on the sieves in
the flour mill. Encapsulated ferrous sulfate is preferred over
elemental Fe powders as the Fe fortificant for wheat flour(1).
It is better absorbed and, like the elemental Fe powders, it
causes no fat oxidation during storage. The present study is
the first to confirm the expected high efficacy of encapsulated
ferrous sulfate in wheat flour.
Regular encapsulated ferrous sulfate is reported to be about
four to ten times the cost of ferrous sulfate. Reducing the size
of the ferrous sulfate particles before encapsulation would be
expected to add an additional cost. It should be noted that the
encapsulated small-sized ferrous sulfate used in the study is an
experimental material, which has not been commercialised.
Electrolytic Fe powder is the most expensive elemental Fe
powder and is similar in cost to ferrous sulfate, whereas
reduced Fe and atomised Fe powders are much cheaper(1,5).
A second objective of the present study was to investigate the
potential of wheat flour as a vehicle for co-fortification with Fe
and iodine. There was a significant increase in the median urin-
ary iodine concentration in the group receiving the microencap-
sulated Fe and iodine, indicating that the iodine was released
from the capsule and was absorbed. This finding is consistent
with a previous study where encapsulated ferric pyrophosphate
and potassium iodate added to salt improved the iodine status
of Moroccan schoolchildren(11,28). Salt is still the preferred
vehicle for iodine fortification in most countries, although par-
ticularly in poor rural areas of North Africa, the Middle East
and South Asia, wheat flour is an important dietary staple and
is often centrally processed, whereas salt is provided by many
small local producers making it difficult to fortify(11,28). In
these regions, wheat flour could be an effective alternative
and/or adjunct vehicle for iodine.
In conclusion, the newly developed H-reduced Fe Nutra-
Finee RS is not an efficacious Fe fortificant for wheat flour.
As a consequence, electrolytic Fe, at double the Fe concen-
tration of ferrous sulfate, should remain the only elemental
Fe powder recommended for wheat flour fortification(1). The
Kuwait wheat flour fortification programme has been advised
to use electrolytic Fe. In view of the somewhat surprising
result with NutraFinee RS, however, it may be worth repeat-
ing the study in an alternative population and include a direct
comparison of NutraFinee RS with electrolytic Fe. In future,
Fe powder manufacturers developing new H-reduced Fe pow-
ders should aim for solubility values in dilute acid similar to
electrolytic Fe before conducting human or animal studies.
This appears to be possible, as demonstrated by the Ho¨gana¨s
experimental Fe powder ‘Hi-Sol’(15), which so far has not
been accepted as commercially viable. An important key to
understanding the solubility of the different Fe powders in
the gastric contents is a better knowledge of their polycrystal-
line structures. Although ferrous sulfate and ferrous
fumarate are the first-choice Fe compounds for wheat flour
fortification, addition of these compounds often leads to ran-
cidity during storage or transport. Under these circumstances,
encapsulated ferrous sulfate is the next best alternative
and, once they are manufactured commercially, the newly
developed small particle-sized microcapsules of Fe and
iodine offer the possibility of fortifying wheat flour in a way
which will improve both Fe and iodine status.
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